Bluebird Bio Financials

Earnings View

Profitability View

Liquidity View

Fundamentals View

Competition View

Bluebird Bio Stock Summary

Bluebird Bio competes with Mersana Therapeutics, Zentalis Pharmaceuticals, Y MAbs, Travere Therapeutics, and Madrigal Pharmaceuticals. bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Cambridge, Massachusetts. Bluebird Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 518 people.

Bluebird Bio Key Financial Ratios

Bluebird Bio Key Balance Sheet Accounts

Bluebird Bio Key Income Statement Accounts

Bluebird Bio Key Cash Accounts

Bluebird Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Bluebird Bio's current stock value. Our valuation model uses many indicators to compare Bluebird Bio value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Bluebird Bio competition to find correlations between indicators driving Bluebird Bio's intrinsic value. More Info.Bluebird bio is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At present, Bluebird Bio's Return On Equity is projected to slightly decrease based on the last few years of reporting. Comparative valuation analysis is a catch-all technique that is used if you cannot value Bluebird Bio by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Bluebird bio Systematic Risk

Today, most investors in Bluebird Bio Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Bluebird Bio's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Bluebird Bio growth as a starting point in their analysis.

Along with financial statement analysis, the daily predictive indicators of Bluebird Bio help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Bluebird bio. We use our internally-developed statistical techniques to arrive at the intrinsic value of Bluebird bio based on widely used predictive technical indicators. In general, we focus on analyzing Bluebird Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Bluebird Bio's daily price indicators and compare them against related drivers.

When running Bluebird Bio's price analysis, check to measure Bluebird Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bluebird Bio is operating at the current time. Most of Bluebird Bio's value examination focuses on studying past and present price action to predict the probability of Bluebird Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bluebird Bio's price. Additionally, you may evaluate how the addition of Bluebird Bio to your portfolios can decrease your overall portfolio volatility.